schliessen

Filtern

 

Bibliotheken

Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma

Compared with conventional chemotherapy, use of liposomes loaded with therapeutic agents is less toxic and more effective in experimental tumours in vivo. We have assessed efficacy and toxicity of liposomal daunorubicin (40mg/[m.sub.2] every 2 weeks) in 25 patients with HIV-associated Kaposi's sarco... Full description

Journal Title: The Lancet 15 May 1993, Vol.341(8855), pp.1242-1243
Main Author: Presant, C.A
Other Authors: Scolaro, M , Kennedy, P , Blayney, D.W , Flanagan, B , Lisak, J , Presant, J
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/0140-6736(93)91147-E
Link: https://www.sciencedirect.com/science/article/pii/014067369391147E
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_0140_6736_93_91147_E
title: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
format: Article
creator:
  • Presant, C.A
  • Scolaro, M
  • Kennedy, P
  • Blayney, D.W
  • Flanagan, B
  • Lisak, J
  • Presant, J
subjects:
  • Medicine
ispartof: The Lancet, 15 May 1993, Vol.341(8855), pp.1242-1243
description: Compared with conventional chemotherapy, use of liposomes loaded with therapeutic agents is less toxic and more effective in experimental tumours in vivo. We have assessed efficacy and toxicity of liposomal daunorubicin (40mg/[m.sub.2] every 2 weeks) in 25 patients with HIV-associated Kaposi's sarcoma of poor prognosis. In 24 evaluable patients, there were 2 complete remissions (8-3%) and 13 partial remissions (54-2%). 5 of 11 patients with doxorubicin-resistant Kaposi's sarcoma had partial remissions. Median duration of response was 12 weeks. Quality of life improved after treatment with a response rate of 71% for physical performance and 74% for emotion. Myelosuppression was the commonest adverse event. Vomiting, stomatitis, and alopecia were rare and mild. Liposomal daunorubicin is safe and effective in HIV-associated Kaposi's sarcoma and improves quality of life. The treatment is effective even in patients resistant to other chemotherapy.
language: eng
source:
identifier: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/0140-6736(93)91147-E
fulltext: fulltext
issn:
  • 0140-6736
  • 01406736
  • 1474-547X
  • 1474547X
url: Link


@attributes
ID471751453
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_0140_6736_93_91147_E
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_0140_6736_93_91147_E
sourcesystemOther
dbid
01RT
1457
24G.
37-5
49JM
5ACRLP
6AEKER
7AFKWA
8AFTJW
9AHHHB
10AITUG
11BNPGV
12EO8
13EO9
14EP2
15EP3
16FDB
17FGOYB
18FIRID
19FNPLU
20G-Q
21J1W
22P-9
23R2-
24SAD
25SDF
26SEL
27SES
28Z5R
pqid198993154
galeid13977217
display
typearticle
titleLiposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
creatorPresant, C.A ; Scolaro, M ; Kennedy, P ; Blayney, D.W ; Flanagan, B ; Lisak, J ; Presant, J
ispartofThe Lancet, 15 May 1993, Vol.341(8855), pp.1242-1243
identifier
subjectMedicine
languageeng
source
descriptionCompared with conventional chemotherapy, use of liposomes loaded with therapeutic agents is less toxic and more effective in experimental tumours in vivo. We have assessed efficacy and toxicity of liposomal daunorubicin (40mg/[m.sub.2] every 2 weeks) in 25 patients with HIV-associated Kaposi's sarcoma of poor prognosis. In 24 evaluable patients, there were 2 complete remissions (8-3%) and 13 partial remissions (54-2%). 5 of 11 patients with doxorubicin-resistant Kaposi's sarcoma had partial remissions. Median duration of response was 12 weeks. Quality of life improved after treatment with a response rate of 71% for physical performance and 74% for emotion. Myelosuppression was the commonest adverse event. Vomiting, stomatitis, and alopecia were rare and mild. Liposomal daunorubicin is safe and effective in HIV-associated Kaposi's sarcoma and improves quality of life. The treatment is effective even in patients resistant to other chemotherapy.
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/014067369391147E$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Presant, C.A
1Scolaro, M
2Kennedy, P
3Blayney, D.W
4Flanagan, B
5Lisak, J
6Presant, J
titleLiposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
subjectMedicine
general
0English
1Elsevier Ltd
210.1016/0140-6736(93)91147-E
3ScienceDirect (Elsevier B.V.)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_0140_6736_93_91147_E
issn
00140-6736
101406736
21474-547X
31474547X
rsrctypearticle
creationdate1993
addtitleThe Lancet
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
01RT
1457
24G.
37-5
49JM
5ACRLP
6AEKER
7AFKWA
8AFTJW
9AHHHB
10AITUG
11BNPGV
12EO8
13EO9
14EP2
15EP3
16FDB
17FGOYB
18FIRID
19FNPLU
20G-Q
21J1W
22P-9
23R2-
24SAD
25SDF
26SEL
27SES
28Z5R
startdate19930515
enddate19930515
lsr40The Lancet, 15 May 1993, Vol.341 (8855), pp.1242-1243
doi10.1016/0140-6736(93)91147-E
citationpf 1242 pt 1243 vol 341 issue 8855
lsr30VSR-Enriched:[pqid, description, galeid]
sort
titleLiposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
authorPresant, C.A ; Scolaro, M ; Kennedy, P ; Blayney, D.W ; Flanagan, B ; Lisak, J ; Presant, J
creationdate19930515
lso0119930515
facets
frbrgroupid7263063648304471168
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier B.V.)
prefilterarticles
rsrctypearticles
creatorcontrib
0Presant, C.A
1Scolaro, M
2Kennedy, P
3Blayney, D.W
4Flanagan, B
5Lisak, J
6Presant, J
jtitleLancet
creationdate1993
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Presant
1Scolaro
2Kennedy
3Blayney
4Flanagan
5Lisak
aufirst
0C.A
1M
2P
3D.W
4B
5J
auinitC
auinit1C
au
0Presant, C.A
1Scolaro, M
2Kennedy, P
3Blayney, D.W
4Flanagan, B
5Lisak, J
6Presant, J
atitleLiposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
jtitleThe Lancet
risdate19930515
volume341
issue8855
spage1242
epage1243
pages1242-1243
issn0140-6736
eissn1474-547X
formatjournal
genrearticle
ristypeJOUR
pubElsevier Ltd
doi10.1016/0140-6736(93)91147-E
lad01The Lancet
date1993-05-15